Clinical Trials

The pupose of this study is to determine the effect of exercise on patients with an acute deep vein thrombosis.

The purpose of this study is to determine whether prescribing apixaban (Eliquis®) is more effective in treating and preventing pulmonary embolisms and subsequent DVTs than monitoring the calf DVT with ultrasound imaging alone.

Determine if the use of sequential pneumatic compression in the arm can prevent the formation of venous clots related to the presence of a peripherally inserted central catheter (PICC).

The purpose of this study is to complete the following aims:

Aim 1: Evaluate initial thrombus characteristics by ultrasound (US) shear wave elastography (SWE) in acute, proximal, deep venous thrombus (DVT).

Aim 2: Prospectively evaluate the role of venous hemodynamics on acute proximal DVT resolution and post-thrombotic syndrome (PTS).

Aim 3: Examine biomarkers of coagulation as predictors of acute proximal DVT resolution and PTS.

Aim 4: Expand the scope of the Mayo Clinic VTE registry to include high quality outcome data on post-thrombotic syndrome.

The purpose of this study is to identify susceptibility genes for venous thromboembolism (VTE) using conventional and novel genetic-epidemiologic methods in high-risk VTE families.

This is a biomarker correlate study for a study which is randomizing patients with calf deep venous thrombosis (calf vein clots) to treatment with blood thinners or not to see if the blood thinner is necessary. 

The purpose of this study is to determine whether a specific external compression pump called the AVT pump can improve blood flow to the skin of the feet in patients with circulatory problems involving the arteries or veins of the legs. The use of the AVT pump in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study.

The purpose is to create a registry of patients at Mayo Clinic who are prescribed the new novel anticoagulation therapy with either rivaroxaban, dabigatran, apixaban, oe edoxaban to allow post marketing survelliance with particular attention to cancer patients treated with novel anticoalants which in marketing studies the patient numbers were small. We also want to compare efficacy and safety of novel anticoagulants to "traditional" anticoagulants such as warfarin and low molecular weight heparin (LMWH) and therefore to register patients treated with this type of anticoagulation to our registry too.

Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease. Massive bleeding from injury accounts for half of early deaths after trauma. This study aims to prevent the deaths and suffering associated with venous thromboembolism and bleeding by identifying the individual person at high risk of these complications in order to take preventive measures.

The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent development of post-thrombotic syndrome (PTS). Additionally, to learn whether a more detailed imaging of the affected lower extremities will provide a more accurate and reliable method to guide treatment for this condition.

The purpose of this study is to investigate the effectiveness and safety of Rivaroxaban for reducing the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpatients with acute, symptomatic COVID-19 infection.

The purpose of this study is to create and maintain a clinical database of patients with history of, or who are at high risk for thromboembolic diseases, along with a plasma/serum repository. We plan to evaluate novel biomarkers that might be associated with thromboembolic diseases and test whether these biomarkers will help predict the incident and recurrentrecurrences of thromboembolic episodes and other outcomes (e.g., mortality, post thrombotic syndrome).